Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma.
- DOI
- 10.1182/bloodadvances.2022008866
- Published
- 2023 Oct 10
- Container
- Blood advances
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1182/bloodadvances.2022008866,
title = {Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma.},
author = {Derman BA and Zonder J and Reece D and Cole C and Berdeja J and Stefka AT and Major A and Kin A and Griffith K and Jasielec J and Jakubowiak AJ},
year = {2023},
journal = {Blood advances},
doi = {10.1182/bloodadvances.2022008866},
url = {https://doi.org/10.1182/bloodadvances.2022008866}
}RIS
TY - JOUR TI - Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma. AU - Derman BA AU - Zonder J AU - Reece D AU - Cole C AU - Berdeja J AU - Stefka AT AU - Major A AU - Kin A AU - Griffith K AU - Jasielec J AU - Jakubowiak AJ PY - 2023 JO - Blood advances DO - 10.1182/bloodadvances.2022008866 UR - https://doi.org/10.1182/bloodadvances.2022008866 ER -
APA
BA, D., J, Z., D, R., C, C., J, B., AT, S., A, M., A, K., K, G., J, J., & AJ, J. (2023). Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma.. Blood advances. https://doi.org/10.1182/bloodadvances.2022008866
Source records
- pubmed · retrieved 2026-09-27T11:27:38.739Z